Brokers Issue Forecasts for iBio’s Q2 Earnings (NASDAQ:IBIO)

iBio, Inc. (NASDAQ:IBIO – Free Report) – Equities researchers at HC Wainwright lowered their Q2 2027 EPS estimates for iBio in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for iBio’s current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for iBio’s Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.73) EPS, FY2029 earnings at ($0.65) EPS and FY2030 earnings at ($0.78) EPS.

A number of other research analysts have also recently commented on IBIO. Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a research report on Monday, September 21st. Wall Street Zen upgraded shares of iBio from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $6.00.

Read Our Latest Research Report on IBIO

iBio Price Performance

Shares of NASDAQ:IBIO opened at $0.71 on Tuesday. The company has a market capitalization of $49.79 million, a P/E ratio of -2.52 and a beta of 1.47. iBio has a 1 year low of $0.68 and a 1 year high of $3.82. The business’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $1.62.

iBio (NASDAQ:IBIO – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $0.03 million.

Institutional Investors Weigh In On iBio

Hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC increased its position in iBio by 51.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company’s stock valued at $5,904,000 after acquiring an additional 1,050,000 shares during the period. Squarepoint Ops LLC acquired a new position in shares of iBio during the second quarter worth $873,000. ADAR1 Capital Management LLC lifted its holdings in shares of iBio by 15.9% during the first quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company’s stock worth $893,000 after purchasing an additional 64,347 shares during the period. Walleye Capital LLC lifted its holdings in shares of iBio by 95.9% during the first quarter. Walleye Capital LLC now owns 388,554 shares of the company’s stock worth $738,000 after purchasing an additional 190,179 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of iBio by 150.8% in the first quarter. Bank of America Corp DE now owns 290,413 shares of the company’s stock worth $552,000 after purchasing an additional 174,620 shares during the last quarter. 7.90% of the stock is currently owned by institutional investors and hedge funds.

More iBio News

Investors following IBIO have been watching these news items:

  • Positive Sentiment: iBio reported 28-week results for its experimental obesity antibody IBIO-610 in obese non-human primates: body weight was 2.3% lower relative to vehicle, fat measures were reduced, lean mass was generally maintained, and Activin E suppression persisted. The company also reported reduced food intake in rats with an experimental amylin candidate. These results could bolster confidence in its obesity pipeline, though they are preclinical and do not establish benefit in people. iBio preclinical data announcement
  • Neutral Sentiment: HC Wainwright kept its Buy rating and $7 price target, but that endorsement came alongside lower earnings forecasts. iBio analyst coverage
  • Negative Sentiment: HC Wainwright cut projected EPS across fiscal 2027–2030 and for each listed 2027 quarter, signaling expectations for deeper losses. Its FY2027 estimate moved to a loss of $0.38 per share from $0.30, while FY2028–FY2030 forecasts also worsened. This could weigh on sentiment, particularly as the company remains loss-making. iBio analyst coverage

iBio Company Profile

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Featured Articles

Earnings History and Estimates for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.